Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region

Aim: The purpose of this study was to examine the phenotypic and genetic characteristics of patients with type 2 diabetes mellitus (T2DM) with different responses to treatment with metformin (MF) in the Novosibirsk region. Materials and methods: We examined 460 patients with T2DM in the Novosibirsk...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina A. Bondar, Olesya Y. Shabelnikova, Ekaterina A. Sokolova, Olga V. Pyankova, Maksim L. Filipenko
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	type 2 diabetes mellitus metformin atm (rs11212617). Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/459e2d5b4e0f4957b2b91801208fd9af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:459e2d5b4e0f4957b2b91801208fd9af
record_format	dspace
spelling	oai:doaj.org-article:459e2d5b4e0f4957b2b91801208fd9af2021-11-14T09:00:20ZPhenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region2072-03512072-037810.14341/DM2004146-47https://doaj.org/article/459e2d5b4e0f4957b2b91801208fd9af2016-05-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7227https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim: The purpose of this study was to examine the phenotypic and genetic characteristics of patients with type 2 diabetes mellitus (T2DM) with different responses to treatment with metformin (MF) in the Novosibirsk region. Materials and methods: We examined 460 patients with T2DM in the Novosibirsk region. Patients were divided into groups according to their HbA1c level: patients who achieved the target HbA1c level during MF therapy (n = 209) and those who did not reach the target HbA1c level (n=251). Genotyping of ATM (rs11212617) was performed using polymerase chain reaction by TaqMan. Results: Patients who achieved the target HbA1c level during MF treatment (good response) were older (61. 1±9. 1 years vs. 57. 4±8. 4 years, p=0. 001), had later onset of diabetes (54. 6 ± 10. 1 years vs. 49. 2±8. 5 years, p = 0. 0001) and shorter duration of diabetes (6. 5±5. 9 years vs. 8. 2±6. 1 years, p=0. 03) compared with those who did not achieve the target HbA1c level. There was no statistically significant association between ATM rs11212617 and achieving the target HbA1c level among all patients [odds ratio (OR)=0. 94, 95% confidence interval = (0. 73–1. 23), p=0. 67] or those with MF monotherapy [OR=0. 90, (0. 65–1. 25), p=0. 54] or combination therapy [OR=1. 02, (0. 72–1. 43), p=0. 92]. There was an effect of age on response to MF therapy in all three groups (all patients: p=0. 001, MF monotherapy group: p=0. 04, combination therapy group: p=0. 0009). In the MF monotherapy group, low dose MF was associated with a good response (p=0. 03), and in the combination therapy group, males were more likely to have a good response (p=0. 003). Patients with genotype C/C or A/C for ATM (rs11212617) compared with those with genotype A/A were more likely to have high levels of triglycerides [2. 33 (1. 52–4. 2) mmol/l, 2. 09 (1. 35–3. 0) mmol/l and 1. 99 (1. 49–3. 21) mmol/l, respectively, p=0. 001], coronary heart disease (CHD) (13. 4%, 13. 4% and 9. 6%, respectively, p=0. 009) and myocardial infarction (7. 8%, 3. 2% and 4. 0%, respectively, p=0. 001). Conclusion: Patients with T2DM who had a good response to MF therapy were older, more likely to be male and had a later onset of T2DM. Genotype C/C for ATM rs11212617 was associated with high triglycerides, CHD and myocardial infarction. ATM rs11212617 was not associated with response to MF therapy in the Novosibirsk region.Irina A. BondarOlesya Y. ShabelnikovaEkaterina A. SokolovaOlga V. PyankovaMaksim L. FilipenkoEndocrinology Research Centrearticletype 2 diabetes mellitusmetforminatm (rs11212617).Nutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 2, Pp 125-131 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus metformin atm (rs11212617). Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus metformin atm (rs11212617). Nutritional diseases. Deficiency diseases RC620-627 Irina A. Bondar Olesya Y. Shabelnikova Ekaterina A. Sokolova Olga V. Pyankova Maksim L. Filipenko Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region
description	Aim: The purpose of this study was to examine the phenotypic and genetic characteristics of patients with type 2 diabetes mellitus (T2DM) with different responses to treatment with metformin (MF) in the Novosibirsk region. Materials and methods: We examined 460 patients with T2DM in the Novosibirsk region. Patients were divided into groups according to their HbA1c level: patients who achieved the target HbA1c level during MF therapy (n = 209) and those who did not reach the target HbA1c level (n=251). Genotyping of ATM (rs11212617) was performed using polymerase chain reaction by TaqMan. Results: Patients who achieved the target HbA1c level during MF treatment (good response) were older (61. 1±9. 1 years vs. 57. 4±8. 4 years, p=0. 001), had later onset of diabetes (54. 6 ± 10. 1 years vs. 49. 2±8. 5 years, p = 0. 0001) and shorter duration of diabetes (6. 5±5. 9 years vs. 8. 2±6. 1 years, p=0. 03) compared with those who did not achieve the target HbA1c level. There was no statistically significant association between ATM rs11212617 and achieving the target HbA1c level among all patients [odds ratio (OR)=0. 94, 95% confidence interval = (0. 73–1. 23), p=0. 67] or those with MF monotherapy [OR=0. 90, (0. 65–1. 25), p=0. 54] or combination therapy [OR=1. 02, (0. 72–1. 43), p=0. 92]. There was an effect of age on response to MF therapy in all three groups (all patients: p=0. 001, MF monotherapy group: p=0. 04, combination therapy group: p=0. 0009). In the MF monotherapy group, low dose MF was associated with a good response (p=0. 03), and in the combination therapy group, males were more likely to have a good response (p=0. 003). Patients with genotype C/C or A/C for ATM (rs11212617) compared with those with genotype A/A were more likely to have high levels of triglycerides [2. 33 (1. 52–4. 2) mmol/l, 2. 09 (1. 35–3. 0) mmol/l and 1. 99 (1. 49–3. 21) mmol/l, respectively, p=0. 001], coronary heart disease (CHD) (13. 4%, 13. 4% and 9. 6%, respectively, p=0. 009) and myocardial infarction (7. 8%, 3. 2% and 4. 0%, respectively, p=0. 001). Conclusion: Patients with T2DM who had a good response to MF therapy were older, more likely to be male and had a later onset of T2DM. Genotype C/C for ATM rs11212617 was associated with high triglycerides, CHD and myocardial infarction. ATM rs11212617 was not associated with response to MF therapy in the Novosibirsk region.
format	article
author	Irina A. Bondar Olesya Y. Shabelnikova Ekaterina A. Sokolova Olga V. Pyankova Maksim L. Filipenko
author_facet	Irina A. Bondar Olesya Y. Shabelnikova Ekaterina A. Sokolova Olga V. Pyankova Maksim L. Filipenko
author_sort	Irina A. Bondar
title	Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region
title_short	Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region
title_full	Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region
title_fullStr	Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region
title_full_unstemmed	Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region
title_sort	phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in novosibirsk region
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/459e2d5b4e0f4957b2b91801208fd9af
work_keys_str_mv	AT irinaabondar phenotypicandgeneticcharacteristicsofpatientswithtype2diabeteswithdifferentresponsestometformintherapyinnovosibirskregion AT olesyayshabelnikova phenotypicandgeneticcharacteristicsofpatientswithtype2diabeteswithdifferentresponsestometformintherapyinnovosibirskregion AT ekaterinaasokolova phenotypicandgeneticcharacteristicsofpatientswithtype2diabeteswithdifferentresponsestometformintherapyinnovosibirskregion AT olgavpyankova phenotypicandgeneticcharacteristicsofpatientswithtype2diabeteswithdifferentresponsestometformintherapyinnovosibirskregion AT maksimlfilipenko phenotypicandgeneticcharacteristicsofpatientswithtype2diabeteswithdifferentresponsestometformintherapyinnovosibirskregion
_version_	1718429523001737216

Phenotypic and genetic characteristics of patients with type 2 diabetes with different responses to metformin therapy in Novosibirsk region

Ejemplares similares